1. Treatment for multiple myeloma in hospital at home: clinical characteristics and patient care pathways.
- Author
-
Mittaine-Marzac, Bénédicte, De Stampa, Matthieu, Marquestaut, Odile, Georges, Alexandre, Ankri, Joel, and Aegerter, Philippe
- Subjects
HOSPITALS ,PATIENT aftercare ,INJECTIONS ,HOME care services ,QUANTITATIVE research ,MEDICAL protocols ,BORTEZOMIB ,T-test (Statistics) ,TREATMENT effectiveness ,KARNOFSKY Performance Status ,DESCRIPTIVE statistics ,CHI-squared test ,KAPLAN-Meier estimator ,MULTIPLE myeloma ,PATIENT care ,DATA analysis software ,INTRAVENOUS injections ,LONGITUDINAL method ,PATIENT safety ,SUBCUTANEOUS injections ,SYMPTOMS - Abstract
While most patients receive anticancer injection in a conventional hospital, some are treated in hospital at home. Given the lack of data, we seek to determine the clinical characteristics and care pathways of patients benefiting from hospital at home (HAH) for anticancer injection. A longitudinal scheme was conducted about patients with multiple myeloma (MM) starting bortezomib-based regimens in HAH in 2015 with a follow-up to September 2019. 154 patients received bortezomib at home with a mean age of 70.6 years, 72.7% over 65y-old and, a median Karnofsky Performans Status of 70. One-third of the elderly lived alone, 16.1% required domestic help. After a 24-month follow-up, 77.9% of patients were alive. The median overall survival was not reached at 4 years. Between 42.1% and 48.1% of patients returned to HAH for a new line of treatment. Patients were mainly independent and "fit." The involvement of HAH was achieved without safety issues nor compromise long-term outcomes. However, the real-world patterns highlighted that only a small proportion of patients returned to HAH for a new treatment line. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF